Systemlord
Member
Jardiance causes vitamin B12 deficiency, iron deficiency and decreases 1,25-dihydroxyvitamin D.
Could Jardiance cause Iron deficiency? - eHealthMe
We study 47863 people who take Iron deficiency or have Jardiance. No or too few reports of Iron deficiency are found in people who take Jardiance.
www.ehealthme.com
Jardiance and Iron deficiency - a phase IV clinical study of FDA data
Summary:
Iron deficiency is reported only by a few people who take Jardiance.
Could Jardiance cause Vitamin b12 deficiency? - eHealthMe
We study 46617 people who take Vitamin b12 deficiency or have Jardiance. No or too few reports of Vitamin b12 deficiency are found in people who take Jardiance.
www.ehealthme.com
Jardiance and Vitamin b12 deficiency - a phase IV clinical study of FDA data
Summary:
Vitamin b12 deficiency is reported only by a few people who take Jardiance.
Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - Data from a randomized, placebo-controlled study - PubMed
Empagliflozin treatment of patients with T2D transiently increases serum phosphate, PTH and FGF23, and decreases 1,25-dihydroxyvitamin D. This might reflect a temporal increase of sodium driven phosphate reabsorption in the proximal tubule of the kidney caused by increased sodium availability in...
pubmed.ncbi.nlm.nih.gov
Methods: In this placebo-controlled, randomized, double-blind study patients with T2D were randomized to empagliflozin 10 mg (n = 20) or placebo (n = 22). Biomarkers of calcium and phosphate homeostasis were assessed before, and after 3 days and 3 months of treatment.
Results: After 3 days of treatment empagliflozin significantly increased serum levels of phosphate (baseline: 1.10 ± 0.21 mmol/L; day 3: 1.25 ± 0.23 mmol/L; p = 0.036), parathyroid hormone (PTH) (baseline: 57.40 ± 30.49 pg/mL; day 3: 70.23 ± 39.25 pg/mL; p = 0.025), fibroblast growth factor 23 (FGF23) (baseline: 77.92 ± 24.31 pg/mL; day 3: 109.18 ± 58.20 pg/mL; p = 0.001) and decreased 1,25-dihydroxyvitamin D (baseline: 35.01 ± 14.01 ng/L; day 3: 22.09 ± 10.02 mg/L; p < 0.001), while no difference of these parameters was recorded after 3 months of treatment. Empagliflozin had no significant effects on serum calcium and markers of bone resorption (collagen type 1 β-carboxy-telopeptide = β-CTX) or formation (osteocalcin) after 3 days and 3 months of treatment.
Conclusions: Empagliflozin treatment of patients with T2D transiently increases serum phosphate, parathyroid hormone and fibroblast growth factor, and decreases 1,25-dihydroxyvitamin D. This might reflect a temporal increase of sodium driven phosphate reabsorption in the proximal tubule of the kidney caused by increased sodium availability in response to SGLT2 inhibition.
Last edited: